2023年12月13日 · Hemophilia is a rare genetic bleeding disorder in which a person inherits problems with certain blood clotting factors, making them unable to work properly. Blood-clotting factors are needed to help stop bleeding after a cut or injury and to prevent spontaneous bleeding. Hemophilia genes can contain many different...

Tell your doctor if you have ever had a bleeding or blood clotting disorder such as hemophilia. Follow your doctor's instructions about using this medicine if you are pregnant. Caplacizumab may increase the risk of bleeding in both mother and baby. However, the benefit of treating aTTP in the mother during pregnancy may outweigh those risks.

Hemophilia A, also called classic hemophilia, is caused by a lack of active clotting factor VIII (8). It is the most common type of hemophilia. Hemophilia B, also called Christmas disease, is caused by a lack of active clotting factor IX (9). It is less common than Hemophilia A. Hemophilia usually runs in families and almost always affects males.

What is von Willebrand disease? Von Willebrand disease is a bleeding disorder. When you have this problem, it takes longer for your blood to form clots, so you bleed for a longer time than other people. Normally when a person starts to bleed, small blood cells called platelets go to the site of the bleeding. These cells...

Disclaimer. Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health …

an Acquired Brain Injury diagnosis, neurofeedback for any diagnosis except an Acquired Brain Injury diagnosis, employment counseling, back school, return to work services, work hardening programs, driving safety, and services, training, educational therapy or other non-

Cigna Healthcare

Title: DG23640_CIGNA-1453413009_24_m-25-rx-all-981597-accredo-flyer_v2.indd Created Date: 9/18/2024 9:11:40 AM

• Hemophilia • Hepatitis C • Hereditary angioedema • Hereditary tyrosinemia • Immune deficiency • Lysosomal storage disorders • Multiple sclerosis • Neutropenia • Orphan and ultra-orphan conditions • Osteoarthritis • Osteoporosis • Psoriasis • Pulmonary arterial hypertension • Respiratory syncytial virus ...

A one-time gene therapy drug with a projected cost of $2.9M 9 indicated for the treatment of adults with severe hemophilia A. For existing Embarc Benefit Protection clients with effective dates of September 1, 2023 or earlier, all customers who meet the solution’s clinical and network criteria for ROCTAVIAN will be able to access the therapy ...